Publications by authors named "O Schorr"
The synthetic tetrahydrocannabinol-analog nabilone improved non-motor symptoms (NMS) in Parkinson's disease (PD) patients in a placebo-controlled, double-blind, parallel-group, randomized withdrawal trial with enriched enrollment (NMS-Nab-study). This was a single-center open-label extension study to assess the long-term safety and efficacy of nabilone for NMS in PD. To be eligible for this study, patients had to be treatment responders during the previous NMS-Nab-trial and complete its double-blind phase without experiencing a drug-related serious/severe/moderate adverse event (AE).
View Article and Find Full Text PDFAims Of The Study: Since 2014, the Swiss Hepatitis Strategy (SHS) has targeted the elimination of Hepatitis C Virus (HCV) in Switzerland. The epidemiology of HCV is diverse across Swiss cantons, therefore cantonal-level screening and treatment strategies should be developed. This study aimed to identify scenarios to achieve HCV elimination in the canton of Bern by 2030.
View Article and Find Full Text PDFBackground: Recurrent falls represent a major source of serious adverse health outcomes in the general older population. Gait impairment has been linked to recurrent falls, but there are only limited long-term data on this association.
Objectives: The objective of the study was to investigate the association of gait disorders (GDs) and gait tests with future falls in an existing longitudinal population-based cohort.
Article Synopsis
- Gait impairment is a major issue in parkinsonian syndromes, with increased variability linked to instability and fall risk.
- The study compared gait variability at different walking speeds among patients with multiple system atrophy (MSA), idiopathic Parkinson's disease (PD), and older adult controls using sensor-based analysis.
- Results indicated that MSA patients exhibited greater gait variability across all speeds compared to controls and PD patients, particularly in swing time and stride length, pointing to significant postural instability in the MSA group.
Objective: To evaluate the decrease of cartilage destruction by a novel orally active and specific matrix metalloproteinase 13 (MMP-13) inhibitor in three different animal models of rheumatoid arthritis (RA).
Materials And Methods: The SCID mouse co-implantation model of RA, the collagen-induced arthritis (CIA) model in mice and the antigen-induced arthritis model (AIA) in rabbits were used.
Results: In the SCID mouse co-implantation model, the MMP-13 inhibitor reduced cartilage destruction by 75%.